NCI-H441Homo sapiens (Human)Cancer cell line

Also known as: NCIH441, NCI-441, NCI-H441-4, H-441, H441

🤖 AI SummaryBased on 12 publications

Quick Overview

Human lung cancer cell line with club cell origin, used in cancer research.

Detailed Summary

The NCI-H441 cell line is a human lung cancer cell line derived from a bronchiolar epithelial cell. It is characterized as a club cell, which is a type of airway epithelial cell involved in the production of surfactant and other secretory products. This cell line is commonly used in research related to lung cancer, particularly in studies involving the molecular mechanisms of tumor development and drug sensitivity. The cell line has been utilized in various studies to investigate the role of specific genes and pathways in cancer progression, including the identification of potential therapeutic targets. Research on NCI-H441 has contributed to understanding the genetic and molecular alterations associated with lung cancer, providing insights into the development of targeted therapies.

Research Applications

Lung cancer researchMolecular mechanisms of tumor developmentDrug sensitivity studiesIdentification of therapeutic targets

Key Characteristics

Derived from bronchiolar epithelial cellsExpresses club cell markersUsed in studies of lung cancer biology
Generated on 6/17/2025

Basic Information

Database IDCVCL_1561
SpeciesHomo sapiens (Human)
Tissue SourcePericardial effusion[UBERON:UBERON_0002409]

Donor Information

Age33
Age CategoryAdult
SexMale

Disease Information

DiseaseLung papillary adenocarcinoma
LineageLung
SubtypeLung Adenocarcinoma
OncoTree CodeLUAD

DepMap Information

Source TypeATCC
Source IDACH-000638_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg158Leu (c.473G>T)Homozygous-PubMed=30737244
MutationSimpleKRASp.Gly12Val (c.35G>T)HeterozygousAcquiredUnknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
11,12
D12S391
19.3
D13S317
9
D16S539
9,13
D18S51
18,19
D19S433
14
D21S11
32.2
D2S1338
17,19
D2S441
14
D3S1358
18
D5S818
11,12
D6S1043
17
D7S820
10
D8S1179
8,14
FGA
24,25
Penta D
10,12
Penta E
12
TH01
9.3
TPOX
8,10
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Comparative proteome analysis across non-small cell lung cancer cell lines.

Daub H.

J. Proteomics 130:1-10(2016).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Reconstructing targetable pathways in lung cancer by integrating diverse omics data.

Cao X.-H., Nesvizhskii A.I., Chinnaiyan A.M.

Nat. Commun. 4:2617.1-2617.13(2013).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer.

Cigudosa J.C., Lazo P.A., Sanchez-Cespedes M.

Hum. Mol. Genet. 18:1343-1352(2009).

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Cell 131:1190-1203(2007).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

Mutation and expression of the DCC gene in human lung cancer.";

Yokota J.

Neoplasia 2:300-305(2000).

Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.

Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.

Int. J. Oncol. 15:927-934(1999).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.

Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.

Cancer Res. 46:798-806(1986).

Peripheral airway cell differentiation in human lung cancer cell lines.

Clark J.C., Whitsett J.A.

Cancer Res. 50:5481-5487(1990).

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).